Innovent Biologics, Inc.
(OTC: IVBIY)
|
6:13 PM UTC, 06/26/24 | |||
---|---|---|---|---|
Last: $19.68 | Change: +0.18 | %Change: +0.92% | Volume: 200 |
Open: | $ 19.68 | Volume: | 200 | |
---|---|---|---|---|
High: | $ 19.68 | Yield(%) | 0.00 | |
Low: | $ 19.68 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 7.79B | |
EPS ($) | n/a | Shares Out: | 407.00M |
% Price Change (last 4 weeks): | 1.61 |
---|---|
% Price Change (last 13 weeks): | -0.61 |
% Price Change (last 26 weeks): | -11.98 |
% Price Change (last 52 weeks): | 24.97 |
% Price Change (year to date): | -12.55 |
Return on Equity (%): | -8.77 |
---|---|
Return on Assets (%): | -5.34 |
Return on Invested Capital (%): | -19.55 |
Gross Profit Margin (%): | 81.69 |
---|---|
Net Profit Margin (%): | -16.56 |
Operating Profit Margin (%): | -16.25 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
|
Innovent Biologics, Inc.
168 Dongping Street Suzhou Industrial Park Suzhou JS 215123 Phone: 86.512.69566088 Fax: 86.512.69566088.8348 http://www.innoventbio.com |
Earnings (1year) ($): | -0.37 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 4.36 |
Cash Flow ($): | -0.22 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 9.75 |
Price/Book (x): | 5.03 |
Price/Cash Flow (x): | 185.29 |
Quick Ratio (x): | 2.78 |
---|---|
Current Ratio (x): | 3.00 |
LT Debt/Equity (x): | 19.16 |
Total Debt/Equity (x): | 28.90 |